Toric IOLs represent a valuable tool for managing eyes with preexisting corneal astigmatism and cataract. The AcrySof Toric IOL (Alcon Laboratories, Inc., Fort Worth, TX) was a valuable addition to the cataract surgeon’s armamentarium and is the toric lens we use primarily. The AcrySof platform has a solid history, and studies of the AcrySof SA60AT single-piece acrylic IOL have demonstrated a high level of stability, efficacy, and safety in healthy cataract patients.1-4 In clinical practice, of course, cataracts often occur in aging eyes with comorbidities such as glaucoma. Can patients with concurrent glaucoma and cataract benefit from toric lenses?

CONSIDERATIONS

It stands to reason that, as long as an eye has good central visual field function, it should benefit from a toric IOL, and thus far, our experience with the AcrySof Toric IOL in glaucoma patients has been very positive. Certainly, surgeons should take the standard steps of carefully marking the 90º and 180º axes preoperatively and marking the exact axis intraoperatively.

It is important to note that glaucomatous eyes may not simply have high IOP. They are also more prone to zonular instability than eyes without the disease, and this weakness may be difficult to detect at the slit lamp due to poor pupillary dilation. The surgeon therefore must be watchful during the operative procedure for poor zonular support. In such eyes, the placement of a toric lens may be ill advised, because slippage or rotation of the IOL will affect its refractive power.5 In addition, glaucoma patients in general are at higher risk of capsular phimosis, so surgeons must carefully create an adequately sized capsulorhexis. If there is early evidence of capsular phimosis, the surgeon can apply YAG laser energy to the anterior capsule at the 12-, 3-, 6-, and 9-o’clock positions to create 2- to 3-mm cruciate “incisions.” This step will prevent postoperative contracture of the capsule and possible rotation of the IOL.

COMBINED PROCEDURES

The AcrySof Toric IOL may be used successfully in combined phacotrabeculectomy procedures. The trauma of the combined procedure, however, can induce a significant amount of astigmatism, typically aligned against the rule or with the wound.6,7 The degree of induced astigmatism may decline over time, as the eye heals. Ophthalmologists can take several steps to minimize surgically induced astigmatism. For example, preplacing flap sutures before the eye becomes hypotonous will minimize distortion of the globe. For surgeons who prefer single-site phacotrabeculectomy, there is evidence that a small incision induces less astigmatism, on par with cataract surgery alone.6,8 There are conflicting reports in the literature about whether or not removing sutures early alleviates some of the induced astigmatism.7-9 We remove conjunctival sutures around postoperative week 3. Moreover, we use a purse-string conjunctival closure, which, in a published study, induced less astigmatism than tight mattress sutures.8

Before implanting a toric IOL in a phacotrabeculectomy procedure, surgeons should determine how much surgically induced astigmatism they can typically expect with their technique 6 months to 1 year postoperatively. That information should be factored into IOL power calculations—an easy step with the AcrySof Toric Calculator (http://www.acrysoftoriccalculator.com).

Probably the biggest concern over using the AcrySof Toric IOL in the setting of a combined procedure is the risk of a flattened anterior chamber with either overfiltration or malignant glaucoma. Theoretically, early postoperative fluctuations in the depth of the anterior chamber could cause the lens to rotate in the bag. We have seen several flat anterior chambers after the placement of a toric IOL. One patient with primary open-angle glauco-
ma underwent combined bleb needling and cataract surgery. The early postoperative course was complicated by hypotony due to overfiltration with flattening of the anterior chamber. This patient required two reformations of the anterior chamber at the slit lamp in the first postoperative week. Six months later, his UCVA was 20/20, with an IOP of 15 mm Hg and no residual astigmatism to suggest significant rotation of the IOL. Another patient with pseudoexfoliation glaucoma developed malignant glaucoma, with increased IOP, corneal edema, and a grade 2 flat chamber 3 days after phacotrabeculectomy (Figures 1 and 2). Fortunately, YAG vitreolysis successfully resolved the crisis. A refraction 6 weeks after the episode suggested slight rotation of the lens (approximately 7º), which did not exceed that reported in straightforward cataract cases. The patient’s refraction and vision were stable 1 year later.

**CONCLUSION**

We now have over a year and a half of experience with the AcrySof Toric IOL in our glaucoma patients. We have used toric implants in cataract surgery in cases of established trabeculectomy as well as in the setting of combined phacotrabeculectomy. As long as patients with glaucoma have a strong potential for central vision, they can benefit substantially from a toric IOL.

Kathryn B. Freidl, MD, is a glaucoma fellow at Wills Eye Institute in Philadelphia. She acknowledged no financial interest in the products or company mentioned herein. Dr. Freidl may be reached at kfreidl@gmail.com.

---

**Figure 1.** A flat anterior chamber in an eye with malignant glaucoma.

**Figure 2.** A deepened anterior chamber 3 weeks after vitreolysis, with a well-functioning filtering bleb.

**Marlene R. Moster, MD,** is a professor of ophthalmology at the Thomas Jefferson School of Medicine and is an attending surgeon at Wills Eye Institute, both in Philadelphia. She is a consultant/advisor to and has received lecture fees and grant support from Alcon Laboratories, Inc. Dr. Moster may be reached at (215) 928-3342; marlenemoster@aol.com.

---


---

**SHARE YOUR FEEDBACK**

Would you like to comment on an author’s article? Do you have an article topic to suggest? Do you wish to tell us how valuable *Glaucoma Today* is to your practice? We would love to hear from you. Please e-mail us at gtletters@bmctoday.com with any thoughts, feelings, or questions you have regarding this publication.